ArticlePloS one2009
Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assay.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 101 citations in OpenAlex.
- Development of a Cost-Effective and Low-Toxicity Safranin-Based Assay for DiscoveringJournal of fungi (Basel, Switzerland) · 2026Article
- Antifungal Activity and Genome Mining Reveal Potentiality of Streptomyces sp. VNUA24 as a Biocontrol Agent.The plant pathology journal · 2026Article
- Nature-Derived Ferulic Acid Hybrids with Enhanced Antifungal and Antivirulence Activity AgainstInternational journal of molecular sciences · 2026Article
- Article
- Butyrolactol A enhances caspofungin efficacy via flippase inhibition in drug-resistant fungi.Cell · 2026Article
- Coniontins, lipopetaibiotics active against Candida auris identified from a microbial natural product fractionation library.Nature communications · 2025Article
- Optimized production of concanamycins using a rational metabolic engineering strategy.Metabolic engineering · 2025Article
- Vertebrate and invertebrate animal infection models of Candida auris pathogenicity.Current opinion in microbiology · 2024Review
- Alternative Non-Mammalian Animal and Cellular Methods for the Study of Host-Fungal Interactions.Journal of fungi (Basel, Switzerland) · 2023Review
- Antifungal and Antibiofilm Efficacy of Paeonol Treatment Against Biofilms ComprisingFrontiers in cellular and infection microbiology · 2022Article
- Comprehensive genetic analysis of adhesin proteins and their role in virulence of Candida albicans.Genetics · 2021Article
- Review
- Combination Therapy to Treat Fungal Biofilm-Based Infections.International journal of molecular sciences · 2020Review
- Marine Bioactive Compounds againstAntibiotics (Basel, Switzerland) · 2020Review
- Antifungal drug screening: thinking outside the box to identify novel antifungal scaffolds.Current opinion in microbiology · 2020Review
- Article
- Piperine Impedes Biofilm Formation and Hyphal Morphogenesis ofFrontiers in microbiology · 2020Article
- Efficiency of vanillin in impeding metabolic adaptability and virulence ofCurrent medical mycology · 2020Article
- Review
- Applications of Invertebrate Animal Models to Dimorphic Fungal Infections.Journal of fungi (Basel, Switzerland) · 2018Review
Corrections and comments
- Erratum issuedTempakakis, Emmanouil [corrected to Tampakakis, Emmanouil]
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
Candida albicans, the most common human pathogenic fungus, can establish a persistent lethal infection in the intestine of the microscopic nematode Caenorhabditis elegans. The C. elegans-C. albicans infection model was previously adapted to screen for antifungal compounds. Modifications to this screen have been made to facilitate a high-throughput assay including co-inoculation of nematodes with C. albicans and instrumentation allowing precise dispensing of worms into assay wells, eliminating two labor-intensive steps. This high-throughput method was utilized to screen a library of 3,228 compounds represented by 1,948 bioactive compounds and 1,280 small molecules derived via diversity-oriented synthesis. Nineteen compounds were identified that conferred an increase in C. elegans survival, including most known antifungal compounds within the chemical library. In addition to seven clinically used antifungal compounds, twelve compounds were identified which are not primarily used as antifungal agents, including three immunosuppressive drugs. This assay also allowed the assessment of the relative minimal inhibitory concentration, the effective concentration in vivo, and the toxicity of the compound in a single assay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.